KR960703597A - METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS - Google Patents

METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS Download PDF

Info

Publication number
KR960703597A
KR960703597A KR1019960700340A KR19960700340A KR960703597A KR 960703597 A KR960703597 A KR 960703597A KR 1019960700340 A KR1019960700340 A KR 1019960700340A KR 19960700340 A KR19960700340 A KR 19960700340A KR 960703597 A KR960703597 A KR 960703597A
Authority
KR
South Korea
Prior art keywords
dioxopiperazine
bis
apoptosis
apoptotic
trend
Prior art date
Application number
KR1019960700340A
Other languages
Korean (ko)
Inventor
엘. 토메이 데이비드
Original Assignee
데이비드 엘 토메이
엘엑스알 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 엘 토메이, 엘엑스알 바이오테크놀로지 인코포레이티드 filed Critical 데이비드 엘 토메이
Publication of KR960703597A publication Critical patent/KR960703597A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

본 발명은 방법을 생리학적으로 허용되는 디옥소피페라진의 치료학적으로 효과적인 양을 투여함으로써 아폽토시스를 방지하거나 지연하기 위해 제공된다.The present invention provides a method for preventing or delaying apoptosis by administering a therapeutically effective amount of a physiologically acceptable dioxopiperazine.

Description

아폽토시스 및 관련 상태의 치료방법(METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS)METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 C3H-10T 1/2모델에 의해 측정된 아폽토시스(apoptosis)에 대한 디옥소피페라진의 효과를 도시하는 그래프이다. 제1도의 X축은 log비스(디옥소피페라진)농도로 제공된다. 결과는 표4에서 제공되고 실시예3에서 논의된다.1 is a graph depicting the effect of dioxopiperazin on apoptosis as measured by the C3H-10T 1/2 model. The X axis of FIG. 1 is given in log bis (dioxopiperazin) concentration. The results are provided in Table 4 and discussed in Example 3.

Claims (16)

아폽토시스성 세포사멸을 방지하거나 지연시키는데 충분한 양으로 치료학적으로 효과적이고 생리학적으로 허용되는 디옥소피페라진을 아폽토시스가 일어나는 환자에게 투여하는 것으로 이루어지는 것을 특징으로 하는 아폽토시스의 지연 또는 예방방법.A method of delaying or preventing apoptosis, comprising administering to a patient in which apoptosis occurs a therapeutically effective and physiologically acceptable dioxopiperazine in an amount sufficient to prevent or delay apoptotic cell death. 제1항에 있어서, 아폽토시스는 급성병리학적 추이에 의해 유발되는 것을 특징으로 하는 방법.The method of claim 1, wherein the apoptosis is caused by an acute pathological transition. 제2항에 있어서, 아폽토시스성 추이는 심근중, 경색, 암퇴화, 면역조정, 바이서스성질환, 빈혈증, 신경장애, 신경변성질화, 설사 및 이질, 당뇨병, 근육소모, 신장부전, 신장독성 전립선퇴축, 이식기관의 거부반응, 세포이식물의 쇠약으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.The method according to claim 2, wherein the apoptotic trend is myocardial infarction, infarction, cancer degeneration, immunomodulation, vice versa disease, anemia, neuropathy, neurodegeneration, diarrhea and dysentery, diabetes mellitus, muscle wastage, kidney failure, nephrotoxic prostate Retraction, rejection of transplantation organs, cell decay. 제3항에 있어서, 바이러스성 질환은 사람 면역결핍성 바이러스인 것을 특징으로 하는 방법.The method of claim 3, wherein the viral disease is a human immunodeficiency virus. 제3항에 있어서, 아폽토시스성 추이는 심근경색과 연관되는 것을 특징으로 하는 방법.4. The method of claim 3, wherein the apoptotic trend is associated with myocardial infarction. 제2항에 있어서, 급성병리학적 추이는 일과성 빈혈증이고 아폽토시스는 심근층, 뇌 또는 신장에서 일어나는 것을 특징으로 하는 방법.The method of claim 2, wherein the acute pathological trend is transient anemia and apoptosis occurs in the myocardial layer, brain, or kidney. 제1항에 있어서, 아폽토시스는 관상동맥폐색에 기인한 재관류손상, 척추/두부 손상과 수반되는 심한마비 및 다른 병리학적 손상에 기인한 재관류손상과 연관되는 것을 특징으로 하는 방법.The method of claim 1, wherein the apoptosis is associated with reperfusion injury due to coronary occlusion, severe paralysis associated with spinal / head injury, and other pathological damage. 제1항에 있어서, 디옥소피페라진은 2,3:2,5: 및 2,6-비스(디옥소피페라진)으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.The method of claim 1, wherein the dioxopiperazine is selected from the group consisting of 2,3: 2,5: and 2,6-bis (dioxopiperazine). 제1항에 있어서, 아폽토시스성 추이는 급성심근경색과 연관되고 디옥소피페라진은 2,6-비스(디옥소피페라진)인 것을 특징으로 하는 방법.The method of claim 1, wherein the apoptotic trend is associated with acute myocardial infarction and the dioxopiperazine is 2,6-bis (dioxopiperazin). 제9항에 있어서, 2,6-비스(디옥소피페라진)은 2,6-피페라진디온 4,4'-(1-메틸-1, 2-에탄디일)비스-, (S)(+)인 것을 특징으로 하는 방법.10. The method of claim 9, wherein 2,6-bis (dioxopiperazin) is 2,6-piperazindione 4,4 '-(1-methyl-1,2-ethanediyl) bis-, (S) (+ ). 아폽토시스성 세포사멸을 방지하거나 지연시키는데 충분한 양으로 치료학적으로 효과적이고 생리학적으로 허용되는 디옥소피페라진을 환자에게 투여하는 것으로 이루어지는 것을 특징으로 하는 심근경색후 아폽토시스의 치료방법.A method of treating post-myocardial infarction apoptosis, comprising administering to a patient a therapeutically effective and physiologically acceptable dioxopiperazine in an amount sufficient to prevent or delay apoptotic cell death. 제11항에 있어서, 디옥소피페라진은 관상동맥부전중의 첫번째 징후에서 투여되는 것을 특징으로 하는 방법.The method of claim 11, wherein dioxopiperazine is administered at the first sign of coronary artery failure. 제11항에 있어서, 디옥소피페라진은 심장발작후 적어도 1시간후에 투여되는 것을 특징으로 하는 방법.The method of claim 11, wherein dioxopiperazine is administered at least 1 hour after the heart attack. 제11항에 있어서, 디옥소피페라진은 심장발작후 6시간이내에 투여되는 것을 특징으로 하는 방법.The method of claim 11, wherein dioxopiperazine is administered within 6 hours after the heart attack. 제11항에 있어서, 디옥소피페라진은 2,3:2,5: 및 2,6-비스(디옥소피페라진)으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.12. The method of claim 11, wherein the dioxopiperazine is selected from the group consisting of 2,3: 2,5: and 2,6-bis (dioxopiperazine). 제15항에 있어서, 2,6-비스(디옥소피페라진)은 2,6-피페라진디온 4,4'-(1-메틸-1, 2-에탄디일)비스-, (S)(+)인 것을 특징으로 하는 방법.16. The method of claim 15, wherein 2,6-bis (dioxopiperazin) is 2,6-piperazindione 4,4 '-(1-methyl-1,2-ethanediyl) bis-, (S) (+ ). ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960700340A 1993-07-23 1994-07-22 METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS KR960703597A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9678893A 1993-07-23 1993-07-23
US08/096,788 1993-07-23
PCT/US1994/008268 WO1995003054A1 (en) 1993-07-23 1994-07-22 Methods of treating apoptosis and associated conditions

Publications (1)

Publication Number Publication Date
KR960703597A true KR960703597A (en) 1996-08-31

Family

ID=22259083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700340A KR960703597A (en) 1993-07-23 1994-07-22 METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS

Country Status (7)

Country Link
EP (1) EP0711168A4 (en)
JP (1) JPH09503749A (en)
KR (1) KR960703597A (en)
AU (1) AU7370594A (en)
BR (1) BR9407145A (en)
CA (1) CA2167805A1 (en)
WO (1) WO1995003054A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3866800B2 (en) * 1996-08-29 2007-01-10 東菱薬品工業株式会社 Prophylactic and / or therapeutic agent for apoptosis-related diseases
US6693100B1 (en) 1999-09-10 2004-02-17 Iervant Zarmanian Pharmaceutical compositions for treating psoriasis
HUP0202791A3 (en) * 1999-09-10 2003-02-28 Cyathus Exquirere Pharmaforsch Pharmaceutical compositions for treating psoriasis
AU5150200A (en) * 1999-11-24 2001-06-04 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
US6552025B1 (en) 1999-11-24 2003-04-22 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
WO2004103304A2 (en) 2003-05-15 2004-12-02 Dmi Biosciences, Inc. Treatment of t-cell mediated diseases
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
CN100431534C (en) * 2003-06-24 2008-11-12 康涅狄格大学 Methods of inhibiting vascular permeability and apoptosis
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc Therapeutic methods and compounds
JP2013537195A (en) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション Disease treatment
KR102032400B1 (en) 2011-10-10 2019-10-15 앰피오 파마슈티컬스 인코퍼레이티드 Treatment of degenerative joint disease
CN103841934A (en) 2011-10-10 2014-06-04 安皮奥制药股份有限公司 Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916072D0 (en) * 1989-07-13 1989-08-31 Creighton Andrew M Pharmaceutical compositions
GB9024861D0 (en) * 1990-11-15 1991-01-02 Hellmann Kurt Bis-dioxopiperazines for treating liver tumors

Also Published As

Publication number Publication date
BR9407145A (en) 1996-09-17
AU7370594A (en) 1995-02-20
WO1995003054A1 (en) 1995-02-02
EP0711168A1 (en) 1996-05-15
CA2167805A1 (en) 1995-02-02
EP0711168A4 (en) 1998-04-01
JPH09503749A (en) 1997-04-15

Similar Documents

Publication Publication Date Title
KR960703597A (en) METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS
Kendall et al. The weight of the human thymus gland at necropsy.
Staffurth et al. Arterial embolism in thyrotoxicosis with atrial fibrillation.
Colley et al. The renal lesion in angiokeratoma corporis diffusum
Busquet et al. The surgical significance of the atrial branches of the coronary arteries
Redmond et al. Surgical anatomy of the human spleen
Roberts et al. Mumps of the heart: clinical and pathologic features
Robson The cuticle of Peripatopsis moseleyi
Bell et al. Patterns of aortic Evans blue uptake in vivo and in vitro
Gupta et al. Subsegmentation of the human liver.
Lenegre Bilateral bundle branch block
Eastern et al. Actinic comedonal plaque
DE3418820A1 (en) MEDICINES FOR DIGESTIVE Ulcers
JP2001131049A (en) Skin preparation for external use
Baird et al. The surgical anatomy of the hepatic veins: variations and their implications for auxiliary lobar transplantation
Bell et al. Prevention by whole pancreas transplantation of glomerular basement membrane thickening in alloxan diabetes
Washington et al. Pheochromocytoma of the adrenal medulla: its role in the pathogenesis of a malignant hypertension
Brezis et al. Hypoxic injury to medullary thick ascending limbs in perfused rat kidneys: reversible and irreversible phases
Mabe et al. Chemical sympathectomy reveals pre-and postsynaptic effects of neuropeptide Y (NPY) in the cardiovascular system
Gough et al. Primary sarcoma of the heart: a light and electron microscopic study of two cases.
Fujikura et al. Unilateral thickening of fetal arteries on the placenta resembling arteriosclerosis
De Pasquale et al. A drug used in traditional medicine: Harpagophytum procumbens DC. III. Effects on hyperkinetic ventricular arrhythmias by reperfusion
Loomis Folklore of the Uncorrupted Body
Bowers Reaction of human blood-forming tissues to chronic benzene exposure
Boucaud-Camou Junctional structures in digestive epithelia of a cephalopod

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid